Tuesday, October 30, 2007
The proportion of patients with at least.
A 3-month, double-blind, randomized, parallel-group sketch compared the efficacy and tolerability of two regimens of the lipidosterolic excerption of S. repens (Permixon) Ninety-two men aged 50 long time or older with symptomatic BPH for at least 6 months were randomly allocated to S. repens 160 mg twice/day or 320 mg once/day. Changes from line in IPSS QOL number were measured after 3 months. Scores improved from touchstone in men receiving both dosages at 3 months (4.0 ± 0.7 to 2.9 ± 1.2, p<0.0001,> 1000 patients), S. repens 320 mg (Permixon) and finasteride 5 mg were compared in a 6-month, randomized par tryout in men with moderate BPH. The primary feather QOL end dot was the IPSS uncertainty at 26 weeks. The QOL improved from touchstone in patients receiving S. repens for 26 weeks (3.63 ± 1.28 to 2.25 ± 1.29, p< style="font-weight: bold; font-style: italic;">finasteride mathematical group (3.66 ± 1.17 to 2.15 ± 1.26, p< p="0.14)."> 1-point process in the 7-point scale) regardless of which intervention they received.